

## rezafungin acetate (Rezzayo®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2659	for the treatment of invasive candidiasis in adults.  SMC restriction: use should be on the advice of local microbiologists or specialists in infectious disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/10/2024	13/12/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8645/rezafungin-rezzayo-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8645/rezafungin-rezzayo-final-sept-2024-for-website.pdf</a>				

## selinexor (Nexpvio®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2673	in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	Available in line with local or regional guidance	07/10/2024	13/12/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8646/selinexor-nexpvio-2673-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8646/selinexor-nexpvio-2673-final-sept-2024-for-website.pdf</a>				

<b>selinexor (Nexpovio®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2674	<p>in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p> <p>SMC restriction: restricted for use in patients with lenalidomide-refractory multiple myeloma, and where an anti-CD38 monoclonal antibody is not appropriate.</p>	Available in line with local or regional guidance	07/10/2024	13/12/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8647/selinexor-nexpovio-2674-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8647/selinexor-nexpovio-2674-final-sept-2024-for-website.pdf</a>				

<b>relugolix (Orgovyx®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2678	<p>Indication under review:</p> <ul style="list-style-type: none"> <li>• for the treatment of adult patients with advanced hormone-sensitive prostate cancer</li> <li>• for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy</li> <li>• as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.</li> </ul>	Available in line with local or regional guidance	07/10/2024	13/12/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8644/relugolix-orgovyx-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8644/relugolix-orgovyx-final-sept-2024-for-website.pdf</a>				

<b>faricimab (Vabysmo®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2685	treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). Faricimab offers an additional treatment choice in the therapeutic class of antineovascularisation agents.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/10/2024	13/12/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8641/faricimab-vabysmo-abbreviated-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8641/faricimab-vabysmo-abbreviated-final-sept-2024-for-website.pdf</a>				
<b>pembrolizumab (Keytruda®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2689	as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.  SMC restriction: adults whose tumours express programmed death-ligand 1 (PD-L1) with less than 50% (0 to 49%) tumour proportion score (TPS).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/10/2024	13/12/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8643/pembrolizumab-keytruda-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8643/pembrolizumab-keytruda-final-sept-2024-for-website.pdf</a>				

<b>cemiplimab (Libtayo®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2724	in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in $\geq$ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:  locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.	Not routinely available as not recommended for use in NHS Scotland	07/10/2024	07/10/2024
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8639/cemiplimab-libtayo-non-sub-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8639/cemiplimab-libtayo-non-sub-final-sept-2024-for-website.pdf</a>				
<b>drospirenone (Slynd®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2725	contraception	Not routinely available as not recommended for use in NHS Scotland	07/10/2024	07/10/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8640/drospirenone-slynd-non-sub-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8640/drospirenone-slynd-non-sub-final-sept-2024-for-website.pdf</a>				

nivolumab (Opdivo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2726	in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.	Not routinely available as not recommended for use in NHS Scotland	07/10/2024	07/10/2024
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/8642/nivolumab-opdivo-final-sept-2024-for-website.pdf">https://scottishmedicines.org.uk/media/8642/nivolumab-opdivo-final-sept-2024-for-website.pdf</a>				